Skip to main content

Pairings: Sep 1, 2010

Premium

Emergent Biosolutions has appointed former National Cancer Institute Director John Niederhuber to serve on its board of directors.

Niederhuber was director at NCI from 2005 to 2010, and he recently joined Inova Health System as executive VP and CEO of the Inova Institute for Translational Research and Personalized Medicine. He also still works as an adjunct investigator at NCI’s Center for Cancer Research.


The North Carolina Biotechnology Center has hired Peter Ginsberg to be vice president of business and technology development. Ginsberg formerly was VP of business development and strategic planning at SurModics, and he has served as a consultant for biotech, pharmaceutical, and medical device clients. He also worked at Deephaven Capital Management on healthcare equity investments, he was a managing director and senior biotechnology analyst at Piper Jaffray, and he was a faculty member at the University of Minnesota's Carlson School of Management.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.